NASDAQ:CSTL - Castle Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $64.33
  • Forecasted Upside: 197.15 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$21.65
▲ +2.02 (10.29%)

This chart shows the closing price for CSTL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Castle Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CSTL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CSTL

Analyst Price Target is $64.33
▲ +197.15% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Castle Biosciences in the last 3 months. The average price target is $64.33, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 197.15% upside from the last price of $21.65.

This chart shows the closing price for CSTL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Castle Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2022Canaccord Genuity GroupLower Price Target$80.00 ➝ $65.00High
5/10/2022Robert W. BairdLower Price Target$50.00 ➝ $44.00High
4/5/2022Canaccord Genuity GroupLower Price TargetBuy$94.00 ➝ $80.00High
4/5/2022Canaccord Genuity GroupLower Price TargetBuy ➝ Buy$94.00 ➝ $80.00High
3/1/2022Lake Street CapitalLower Price Target$94.00 ➝ $63.00Medium
3/1/2022Robert W. BairdLower Price Target$82.00 ➝ $60.00High
1/7/2022StephensInitiated CoverageOverweight$59.00Medium
11/9/2021SVB LeerinkLower Price TargetOutperform$85.00 ➝ $75.00High
11/9/2021Robert W. BairdBoost Price TargetOutperform$78.00 ➝ $82.00High
8/10/2021Robert W. BairdBoost Price TargetOutperform$73.00 ➝ $78.00High
7/14/2021SVB LeerinkBoost Price TargetOutperform$80.00 ➝ $85.00High
5/13/2021Robert W. BairdReiterated RatingBuy$73.00High
4/30/2021Lake Street CapitalInitiated CoverageBuy$94.00Low
3/9/2021Robert W. BairdLower Price TargetOutperform$87.00 ➝ $82.00Low
2/3/2021KeyCorpBoost Price TargetOverweight$70.00 ➝ $90.00Low
1/15/2021SVB LeerinkBoost Price TargetOutperform$70.00 ➝ $80.00High
12/17/2020BTIG ResearchBoost Price TargetBuy$60.00 ➝ $80.00High
12/11/2020SVB LeerinkBoost Price TargetOutperform$57.00 ➝ $70.00High
11/9/2020KeyCorpInitiated CoverageOverweight$70.00High
9/25/2020SVB LeerinkBoost Price TargetOutperform$50.00 ➝ $57.00Low
8/11/2020SVB LeerinkBoost Price TargetOutperform$45.00 ➝ $50.00High
5/12/2020SVB LeerinkBoost Price TargetOutperform$40.00 ➝ $45.00High
3/27/2020Robert W. BairdLower Price TargetOutperform$38.00 ➝ $35.00Medium
3/11/2020BTIG ResearchBoost Price Target$32.00 ➝ $41.00High
3/11/2020SVB LeerinkBoost Price TargetOutperform$35.00 ➝ $40.00High
3/11/2020Robert W. BairdBoost Price TargetOutperform$37.00 ➝ $38.00High
9/4/2019SVB LeerinkSet Price TargetBuy$33.00Low
9/4/2019Robert W. BairdBoost Price TargetOutperform$27.00 ➝ $31.00High
9/4/2019BTIG ResearchBoost Price TargetBuy$32.00High
8/19/2019BTIG ResearchInitiated CoverageBuy$25.00High
8/19/2019SVB LeerinkInitiated CoverageOutperform$28.00High
8/19/2019Robert W. BairdInitiated CoverageOutperform$27.00High
(Data available from 5/22/2017 forward)

News Sentiment Rating

-0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/24/2021
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
11/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/23/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
1/22/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
2/21/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/23/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
4/22/2022
  • 2 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 4 very negative mentions
5/22/2022

Current Sentiment

  • 2 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Castle Biosciences logo
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Read More

Today's Range

Now: $21.65
Low: $20.00
High: $21.76

50 Day Range

MA: $30.55
Low: $18.10
High: $45.99

52 Week Range

Now: $21.65
Low: $17.01
High: $78.92

Volume

411,563 shs

Average Volume

413,560 shs

Market Capitalization

$568.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Castle Biosciences?

The following Wall Street analysts have issued reports on Castle Biosciences in the last twelve months: Canaccord Genuity Group Inc., Lake Street Capital, Robert W. Baird, Stephens, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for CSTL.

What is the current price target for Castle Biosciences?

0 Wall Street analysts have set twelve-month price targets for Castle Biosciences in the last year. Their average twelve-month price target is $64.33, suggesting a possible upside of 197.2%.
View the latest price targets for CSTL.

What is the current consensus analyst rating for Castle Biosciences?

Castle Biosciences currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CSTL will outperform the market and that investors should add to their positions of Castle Biosciences.
View the latest ratings for CSTL.

What other companies compete with Castle Biosciences?

How do I contact Castle Biosciences' investor relations team?

Castle Biosciences' physical mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The company's listed phone number is (866) 788-9007 and its investor relations email address is [email protected] The official website for Castle Biosciences is castlebiosciences.com. Learn More about contacing Castle Biosciences investor relations.